Boc-(2R,3S)-3-Phenylisoserine

Catalog No. :
ACAOZK379
CAS No. :
145514-62-1
Molecular Formula :
C14H19NO5
Molecular Weight :
281.31

IUPAC Name:(2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoic acid

Boc-(2R,3S)-3-Phenylisoserine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$86.00Login to see priceIn stockInquiry
250mg95%$129.00Login to see priceIn stockInquiry
1g95%$343.00Login to see priceIn stockInquiry
5g95%$907.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameBoc-(2R,3S)-3-Phenylisoserine
IUPAC Name(2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoic acid
MDL No.MFCD02259481
Molecular FormulaC14H19NO5
Molecular Weight281.31
SMILESO[C@H]([C@H](C1=CC=CC=C1)NC(OC(C)(C)C)=O)C(O)=O
InChI KeyZVAFCKLQJCZGAP-WDEREUQCSA-N
Synonym145514-62-1 | (2R,3S)-boc-3-Phenylisoserine | (2R,3S)-N-Boc-3-Phenylisoserine | Boc-(2R,3S)-3-phenylisoserine | 126252-53-7 | (2R,3S)-3-((tert-Butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoic acid | (2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-pheny
CAS No.145514-62-1
PubChem CID7010687

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACAOZK379 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACWQNV980 route compound structure diagram
    ACWQNV980132201-32-2 In Stock
  4. Then
  5. ACAOZK379 route product structure diagram
    ACAOZK379145514-62-1 In Stock
Inquiry

2. ACAOZK379 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACAOZK379 route product structure diagram
    ACAOZK379145514-62-1 In Stock
Inquiry

Comments (0)